Intellia Therapeutics halted enrollment and dosing across two late‑stage CRISPR trials following a volunteer’s hospitalization with severe liver injury linked to its transthyretin amyloidosis program. The company suspended screening and dosing while it investigates the event and develops an amended safety protocol. The pause affected two Phase 3 studies and triggered sharp investor reaction: shares plunged on the report. Industry observers noted liver toxicity has been a recurring concern for in vivo genome‑editing approaches, prompting sponsors to reassess dosing, delivery and monitoring strategies. Intellia said it is working with investigators and regulators to evaluate causality and next steps; the company’s public statements emphasize patient safety and the need for additional review before resuming enrollment.